Stem cell therapy is a promising strategy for treatment of muscular dystrophies. In addition to muscle fiber formation, reconstitution of functional stem cell pool by donor cells is vital for long-term treatment. We show here that some CD133 + cells within human muscle are located underneath the basal lamina of muscle fibers, in the position of the muscle satellite cell. Cultured hCD133 + cells are heterogeneous and multipotent, capable of forming myotubes and reserve satellite cells in vitro. They contribute to extensive muscle regeneration and satellite cell formation following intramuscular transplantation into irradiated and cryodamaged tibialis anterior muscles of immunodeficient Rag2-/γ chain-/ C5-mice. Some donor-derived satellite cells expressed the myogenic regulatory factor MyoD, indicating that they were activated. In addition, when transplanted host muscles were reinjured, there was significantly more newly-regenerated muscle fibers of donor origin in treated than in control, nonreinjured muscles, indicating that hCD133 + cells had given rise to functional muscle stem cells, which were able to activate in response to injury and contribute to a further round of muscle regeneration. Our findings provide new evidence for the location and characterization of hCD133 + cells, and highlight that these cells are highly suitable for future clinical application.
INTRODUCTION
Determining the optimal muscle stem cells to repair and regenerate skeletal muscle is essential for effective treatment of muscular dystrophies. A suitable stem cell for therapeutic purposes should not only survive and make muscle fibers following transplantation, but also participate in the reconstitution of a functional stem cell pool, able to repair, and regenerate muscle fibers throughout life.
The classical skeletal muscle stem cell is the satellite cell, located in its niche between the sarcolemma and basal lamina of muscle fibers. Satellite cells are a heterogeneous population 1 that are responsible for growth, repair, and regeneration of muscle; mouse satellite cells are also capable of self-renewal, to generate functional satellite cells. 2 Other stem cells, including pericytes, mesoangioblasts, and CD133 + cells that are present within skeletal muscle have been shown to contribute to muscle regeneration in animal models. [3] [4] [5] [6] [7] [8] Among the human muscle-derived stem cells so far investigated, only myoblasts 9, 10 and CD133 + cells 11 give rise to satellite cells after intramuscular transplantation into immunodeficient mice. Although there is evidence that satellite cells formed by injected myoblasts are functional, 9 ,10 the therapeutic potential of human myoblasts is limited by their poor transplantation efficiency (reviewed in ref. 12 ). Thus, the human skeletal muscle-derived CD133 + (hCD133 + ) cell becomes a promising candidate stem cell type for future cell therapy due to its relatively higher transplantation efficiency than human myoblasts, 11 ability to be systemically delivered to skeletal muscle and transducibility by lentiviral vectors. 3, 11 However, the anatomical location of this cell population within human muscle is unknown, and although hCD133 + cells transplanted into mouse muscles were shown to form Pax7 + cells located in the satellite cell position, the functionality of these donor-derived satellite cells was not tested. 11 This is important, as cells from other sources, e.g., the bone marrow, can enter the satellite cell position, but are not functional. 13 Donor-derived satellite cells must be functional to ensure their long-term therapeutic role within the host muscle.
To understand more about the location, phenotype, and long term therapeutic potential of hCD133 + cells, we investigated their anatomical location on transverse sections of human skeletal muscle, examined their characteristics and myogenic properties in vitro and their contribution to muscle regeneration within injured muscles of Rag2-/γ chain-/C5-mice.
We provide the first evidence of the anatomical position of CD133 + cells within human muscle. In addition, we show that hCD133 + cells effectively participate in muscle regeneration and give rise to functional satellite cells after intramuscular transplantation into host mice, evidence that they could be exploited for treating muscular dystrophy.
RESULTS

CD133 + cells are present within normal and
Duchenne muscular dystrophy human muscles, either inside or outside the muscle fiber basal lamina We found no CD133 + cells in muscle sections from two control patients (Table 1 ; patients 1 and 2) which might be due to their extremely low incidence within normal muscle. 3 However, in muscle sections taken from neonatal muscle (from two 18-dayold nondystrophic control patients (Table 1 ; patients 6, 7)), we detected CD133 + cells located at the periphery of the muscle fiber, underneath the basal lamina, coexpressing the satellite cell marker Pax7 (Figure 1a-d) , suggesting that a subset of satellite cells in Figure S3 ).
hCD133 + cells are myogenic in vitro
All preparations of CD133 + cells differentiated into multinucleated myotubes in vitro. One typical cell preparation ( Table 1 ; patient 9) was induced to differentiate for 7 days and quantified at mpd 8.29. As shown in Figure 2a -d, the fusion index of this cell preparation is 42.46 ± 3.01% (mean ± SEM), determined by the percentage of nuclei within myosin+ myotubes/total nuclei; myotubes are defined as containing at least three nuclei. Pax7 + cells (6.2 ± 1.02%, mean ± SEM) were also present between the myotubes, evidence of formation of reserve satellite cells by CD133 + cells during differentiation (Figure 2a-d) .
Dystrophin, a marker of mature myotubes, was expressed in differentiated myotubes derived from CD133 + cells (Figure  2e-h ).
hCD133 + cells contribute to muscle regeneration hCD133 + cells maintained in three different proliferating media were transplanted at mpd 7.15-8.29 into tibialis anterior (TA) muscles of Rag2-/γ chain-/C5-mice. Four weeks after transplantation, human lamin A/C + nuclei and human spectrin + myofibers were detected in all grafted muscles. The number of human lamin A/C + nuclei, human spectrin + fibers, and human spectrin + fibers containing human lamin A/C + nuclei were quantified (Figure 3a-f ) and compared among three groups using one-way analysis of variance followed by Tukey's multiple comparison test.
Overall, hCD133 + cells expanded in all three media contributed to muscle regeneration (Figure 3a-f; Table 2 ). There were no significant differences in the number of donor cells (human lamin A/C + nuclei) among the three groups (P = 0.0856). There were differences in the number of human spectrin + fibers (P = 0.0472) among the three groups. A more rigorous definition of a fiber of human origin is one that contains two human-specific markers, e.g., human spectrin and a human lamin A/C + nucleus (defined here as S+L fibers). [14] [15] [16] Using this criterion to identify fibers of donor origin, we found that there were also significant differences of S+L fibers among the three groups (P = 0.0123). Further, Tukey's multiple comparison test confirms that there were significantly more human spectrin + fibers in muscles of group 1 than in group 2, and significantly more S+L fibers in group 3 than group 2, but there was no difference in the number of S+L fibers between group 1 and 3.
In summary, hCD133 + cells survive in our in vivo mouse model and contribute to robust muscle regeneration after they had been cultured in all three media, but cells maintained in media 1 and 3 contribute to significantly more muscle regeneration than those expanded in medium 2. Subsequent experiments were therefore performed on cells that had been grown in media 1 or 3.
hCD133 + cells that had undergone greater expansion in vitro contribute less to muscle regeneration in vivo
The expansion of mouse and human myoblasts in vitro significantly reduces their contribution to muscle regeneration in mouse models in vivo. 14, 17 To identify whether this is also the case with hCD133 + cells, we transplanted them at low (7.15-8.29) or high (18.19) mpd into our in vivo experimental model, and compared their contribution to muscle regeneration 1 or 3 months after transplantation.
Cells transplanted at the lower mpd gave rise to a similar number of human nuclei, human spectrin + fibers, and human spectrin + fibers containing a human nucleus at 1 and 3 months after grafting. In contrast, although the same cells transplanted at the higher mpd gave rise to similar numbers of human lamin A/C + nuclei 1 and 3 months after grafting, the number of human spectrin + fibers and of S+L fibers were both significantly higher at 1 than at 3 months after transplantation (Figure 3g-l and Table 3 ).
Donor CD133 + cells give rise to Pax7 + cells located both underneath and outside the basal lamina of muscle fibers
Knowing that hCD133 + cells can contribute to muscle regeneration after intramuscular transplantation, the next question we asked was whether they could also form satellite cells. To identify satellite cells of donor origin, we stained transverse sections of group 1 muscles with antibodies to human lamin A/C and the satellite cell marker Pax7 ( Figure 4A ). The number of Pax7 + cells (which include cells of both human and mouse origin) in representative sections of each muscle (n = 8) was 40.5 ± 12.18 (mean ± SEM); the number of human lamin A/C + /Pax7 + cells was 38.25 ± 12.10 (mean ± SEM), which accounts for 91.8 ± 3.5% of total Pax7 + cells, showing that the majority of Pax7 + cells were of human origin ( Figure 4A ). This is not surprising, as the host muscle had been irradiated, which leads to a significant loss of host satellite cells. 18 To determine whether donor-derived Pax7 + cells were in the satellite cell position, triple labeling of human lamin A/C, Pax7, and laminin was performed and the sections were observed under the confocal microscope. Donor-derived Pax7 + cells were located both in the satellite cell position (underneath the basal lamina of myofibers; Figure 4B ) and outside the basal lamina ( Figure  4C ). There were 11.5 ± 4.93 and 26.75 ± 7.42 human lamin A/C + / Pax7 + cells per representative transverse section (equivalent to 24.45 ± 4.64 and 75.55 ± 4.64% of total Pax7 + cells of human origin) located inside and outside basal lamina, respectively, indicating that although donor cells gave rise to Pax7 + cells in vivo, only a quarter of these cells are bone fide satellite cells, the remainder being myoblasts located outside the satellite cell niche.
Donor-derived satellite cells are functional in vivo
For treatment of muscular dystrophies, an ideal stem cell should not only survive and differentiate into muscle fibers to rescue the acute muscle injury, but it should also reconstitute the stem cell pool to fulfill long-term therapeutic benefit to the host muscle. However, a cell of donor origin in the satellite cell position is not necessarily functional.
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A subset of donor-derived satellite cells express MyoD, a marker of activated satellite cells To test the functionality of the hCD133+ cell-derived satellite cells, we firstly examined whether satellite cells of donor origin were able to express MyoD, a marker of either an activated satellite cell, or its proliferating progeny. 19 Multichannel immunostaining ( Figure 5A ) of human lamin A/C, human spectrin, human MyoD, and pan-laminin on sections of mouse muscles that had been transplanted with hCD133 + cells revealed that a subset of human lamin A/C + cells (red), are located outside the muscle fiber sarcolemma (red, human spectrin + fiber), underneath basal lamina (cyan, pan-laminin + ), colocalized with 4′,6-diamidino-2-phenylindole (blue), were also expressing MyoD (green), a marker of activated satellite cells (white arrow; Figure 5A ). In addition, donor nuclei (human lamin A/C + ) expressing human MyoD (green, yellow arrow) but inside the sarcolemma of the myofiber (human spectrin + ) were also seen in the same section, suggesting that these were recently formed myonuclei of human origin within the regenerated muscle fibers.
Cells of hCD133 + origin within grafted muscles formed functional muscle stem cells
The fact that a proportion of donor-derived satellite cells expressed MyoD indicates that they are activated, rather than quiescent, and are therefore to some extent functional. To determine whether the donor-derived satellite cells were indeed fully functional, we tested their response to an imposed injury to the muscle. The finding of newly regenerated muscle fibers of donor origin a week after the grafted, regenerated muscle had been injured by notexin is evidence that the transplanted donor cells had given rise to functional satellite cells in vivo. 2 To our surprise, we found small fibers with high human neonatal myosin expression (i.e., recently regenerated myofibers) 20 in transplanted muscles that had not been injured by notexin. Expression of neonatal myosin suggests that these irradiated, cryodamaged muscles were not fully reinnervated. 21 We also found that the number of recently regenerated fibers closely correlated with the transplantation efficiency, indicated by the number of human spectrin + fibers (Figure 5Ba and b) quantified within the same muscle section. To rule out the effect of the initial transplantation efficiency on the number of recently-regenerated fibers of donor origin, we normalized the number of the recently regenerated fibers to the number of human spectrin + fibers, and compared the muscle treated with notexin to its contralateral, nontreated muscle, analyzed by paired t-test. The ratio of the number of recently regenerated muscle fibers/number of total donor-derived muscle fibers (human spectrin + ) was significantly higher in notexin treated than in nontreated muscles (P = 0.0008), evidence of functional satellite cells of donor origin which gave rise to newly regenerated muscle fibers following injury.
DISCUSSION
The human skeletal muscle-derived CD133 + cell is a promising muscle stem cell type for cell therapy of muscular dystrophies such as DMD. 3, 11 These cells can be expanded in vitro, generating large numbers of cells for transplantation and are myogenic in vitro. Our findings confirm previous work showing that hCD133 + cells contribute to robust muscle regeneration after intramuscular injection in an immunodeficient mouse model. 11 Importantly, we provide novel evidence that the transplanted cells functionally reconstituted the satellite cell pool, suggesting their potential for long-term treatment of muscle diseases.
CD133 is a transmembrane protein which is highly expressed in stem cells such as hematopoietic stem cells, 22 neural stem cells, 23 cancer stem cells, 24 and very small embryonic like stem cells. 25, 26 Although CD133 + cells have been prepared a from human skeletal muscle, 3, 11 the origin of these cells has not been identified. We showed that CD133 + is expressed by a subset of satellite cells (expressing Pax7) in human skeletal muscles. In neonatal normal muscles and postnatal DMD muscles, CD133 + cells were present in the satellite cell position as well as in the interstitium. In contrast, in nondystrophic adult human muscle, no CD133 + cells were seen in the sections examined, although CD133 + cells can be isolated from such muscles. The finding of CD133 + cells within very young normal and DMD muscles and their rarity or absence in muscles derived from two juvenile controls (Table 1 ; patients 1 and 2) suggests that they are implicated in muscle growth and regeneration.
Following their expansion in culture, hCD133 + cells give rise to cells expressing different lineage markers (see Supplementary  Figures S2 and S3) , suggesting that they are either a mixed population of cells within skeletal muscle, or that they are multipotent stem cells, able to give rise to several mesenchymal lineages in culture. They express Pax7, which identifies quiescent satellite cells, in their niche between the basal lamina and sarcolemma of muscle fibers. [27] [28] [29] In injured muscle, satellite cells become activated, proliferate and may leave their niche, to repair neighboring damaged muscle fibers. After proliferation as Pax7/MyoD-expressing myoblasts, most cells maintain MyoD but downregulate Pax7 and commit to myogenic differentiation. Other myoblasts maintain Pax7 but downregulate MyoD, withdraw from the cell cycle, and reexpress markers of quiescent satellite cells, including Pax7. [31] [32] [33] Pax7 therefore identifies both satellite cells and a proportion of their progeny myoblasts. When placed under in vitro conditions that promote myogenic differentiation, hCD133 + cells formed multinucleated myotubes and Pax7 + reserve [34] [35] [36] [37] [38] cells, evidence of myogenic differentiation and contribution to the satellite cell pool.
When transplanted intramuscularly in our mouse model, hCD133 + cells contributed to robust muscle regeneration and also gave rise to functional satellite cells, able to contribute to a further round of muscle regeneration following reinjury of the host muscle (Figures 3-5) .
However, although hCD133 + cells are promising for therapeutic application in muscular dystrophies, particularly for targeted treatment of key muscles by intramuscular delivery, they have several drawbacks. They are very rare within skeletal muscle of normal adults, representing 1% of the total mononucleated muscle cells. 3 They are also very fragile cells; in our hands, they did not survive FACS sorting, necessitating the use of a milder, but possibly less specific method (magnetic-activated cell sorting) to isolate them from skeletal muscle. Expansion of these cells in culture, which would be necessary for clinical application, is challenging. Human blood-derived CD133 + cells are difficult to expand in vitro, 39 and the only medium previously shown to support expansion of muscle-derived CD133 + cells is not readily available. 3, 11 We show that skeletal muscle-derived hCD133 + cells could proliferate in all three different commercially available media that we tested, but that they contributed to muscle regeneration to a significantly greater extent when they had been expanded in M10 and EGM-2 medium than in CD133 + cell proliferation medium. Similarly to myoblasts, prolonged culture of donor hCD133 + cells reduces their effectiveness in vivo. Whether hCD133 + cells prepared from different donors are uniform in their phenotype and differentiative potential is also a concern, but we found no significant differences in the myogenic capacity of cells prepared from paraspinal muscles of all four normal donors.
In addition, the contribution to muscle regeneration of systemically-delivered hCD133 + cells needs to be confirmed, 3 as we failed to obtain any contribution to muscle regeneration from intraarterially delivered hCD133 + cells in our mouse model. This might be due to various factors, including the phenotype of cells used for transplantation, different genetic and immunodeficient background of the recipient mice and the injury models used. As systemic delivery is required for treatment of muscular dystrophies such as DMD, in which muscles are affected body-wide, more efforts are need to explore the mechanism by which donor stem cells transmigrate through the blood vessel and contribute to muscle regeneration in some dystrophic animal models, 3, 4, 7, 8 but not others. 15 Nonetheless, based on our findings that hCD133 + cells are stem cells present within human skeletal muscle and that, apart from myoblasts, they are the only human stem cell that contributes to a functional muscle stem cell pool after transplantation, it is worthwhile to consider moving to clinical trials with these cells. Ideally, to rule out the potential immune rejection by the recipient, hCD133 + cells could be isolated from the patient, manipulated in vitro to express, e.g., dystrophin or an exon-skipping construct, then transplanted back to the patient. Even if hCD133 + cells are not routinely or efficiently systemically deliverable, they would be useful for treatment of key muscles, such as finger muscles in DMD patients, 40 or muscles that are more affected by a muscular dystrophy, e.g., oculopharyngeal muscular dystrophy, in which that eyelid elevator and pharyngeal muscles are primarily affected.
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MATERIALS AND METHODS
Mice were bred and experimental procedures were carried out in the Biological Services Unit, University College London Institute of Child Health, in accordance with the Animals (Scientific Procedures) Act 1986. Experiments were performed under Home Office licence number 70/7086. Experiments were approved by the local University College London ethical committee prior to the licence being granted.
Immunofluorescent staining of human muscle sections. Transverse, cryostat sections of muscle biopsies from control patients (with minimal muscle pathology), young patients (18 days of age, with minimal changes in muscle pathology), and DMD patients were studied. Details of muscle biopsies are listed in Table 1 .
Seven micrometers cryosections were air dried at room temperature (RT) for 30 minutes before being fixed with 4% paraformaldehyde for 15 minutes at RT. The sections were then washed with phosphatebuffered saline (PBS) three times followed by overnight incubation at 4 °C in mouse anti-CD133 (MiltenyiBiotec, 293C3, 1:100, Surry, UK), Pax7 (DHSB, 1:100, Iowa City, IA), and rabbit antipan-laminin (Sigma, 1:1,000, Dorset, UK) diluted in PBS containing 10% normal goat serum and 0.03% Triton X100.
Sections were then washed with PBS and incubated with Alexa-594-conjugated goat antimouse IgG2b, Alexa-647-conjugated goat antimouse IgG1, and Alexa-488-conjugated goat antirabbit IgG (H+L) antibodies (Invitrogen, Paisley, UK) at RT for 1 hour. Sections were then mounted with mounting medium (DAKO, Ely, UK) containing 10 µg/ml 4′,6-diamidino-2-phenylindole. Sections stained with secondary antibody only were used as negative control.
Isolation and maintenance of human muscle CD133 + cells. Biopsies of paraspinal muscle of four adolescent idiopathic scoliosis patients were taken with the patient's consent. Muscles were cut into 1 mm 3 pieces using a scalpel and digested with an enzyme mixture containing collagenase IA-S (Sigma, C9722), II (Sigma, C1764), and IV (Sigma, C1889; 1 mg/ ml each) in 20% fetal bovine serum Dulbecco's modified eagle's medium for 45 minutes at 37 °C. The cell suspension was then diluted with PBS and filtered through a 40 µm cell strainer (SLS, 352340, Nottingham, UK) before centrifuged at 300g for 10 minutes at RT. The resulting pellet was resuspended in 10 ml red cell lysis buffer (Cambridge Bioscience, 10089, Cambridge, UK) for 5 minutes at RT, centrifuged at 300g for 10 minutes at RT. The pellet was then incubated with a dead cell removal kit (MiltenyiBiotec, 130-090-101) and the dead cells removed according to the manufacturer's instructions. The live cells were then centrifuged at 300g for 5 minutes at RT, incubated with antihuman CD133 microbeads (MiltenyiBiotec, 130-050-801), 1:11 at 4 °C for 30 minutes. The CD133 + and CD133 − cell populations were separated using LS column (MiltenyiBiotec, 130-042-401) in a magnetic-activated cell sorting system (MiltenyiBiotec). Resulting CD133 + cells were cultured in three different proliferation media and expanded at 37 °C in 5% O 2 and 5% CO 2 incubator. The media we tested in our study were: (Medium 1): M10 medium: Megacell Dulbecco's modified eagle's medium (M3942, Sigma) containing 10% fetal bovine serum, 2 µmol/l glutamine, 1% nonessential amino acids, 0.1 mmol/l β-mercaptoethanol, and 5 ng/ml basic fibroblast growth factor, a medium shown to support the proliferation of human muscle-derived pericytes 4, 15 . (Medium 2): CD133 + cell proliferation medium (Filarete InvestimentiS.p.a., Milan, Italy). (Medium 3): EGM-2 medium (LONZA, CC-3202, Wolverhampton, UK), a medium used to expand human muscle-derived myoendothelial cells. 42 Plated CD133 + cells started to proliferate 5-10 days after isolation (see Supplementary Figure S1a-c) . Cells were trypsinized when they approached confluence and the cell numbers recorded. For long-term maintenance, cells were plated at a density of 2.5 × 10 5 cells/75 cm 2 flask, with 1 mg/ml collagen I as the substrate and in the media described above. Cells were passaged every 3-4 days, and mean population doublings (mpds) were calculated as previously described. 15 Aliquots of cells were frozen at each passage and stored in liquid nitrogen for future studies.
In vitro characterization of hCD133 + cells. For the cell phenotype assay, 2 × 10 4 cells were plated onto 5 µg/ml poly-d-lysine coated eight-well chamber slides (Fisher Scientific, Loughborough, UK) and incubated for 1-3 days before being processed for immunofluorescent staining. Cells were fixed with 4% paraformaldehyde for 15 minutes and incubated with PBS containing 10% normal goat serum/0.03% Triton X100 for 30 minutes. Cells were then incubated with primary antibodies for 1 hour followed by Alexa 488-conjugated goat antimouse or rabbit IgG (H+L; Invitrogen, 1:500) for 1 hour. All staining procedures were performed at RT. Cells stained with secondary antibody only were used as negative control. For myogenic differentiation, CD133 + cells were plated at 5 × 10 4 cells/ well onto 10 µg/ml laminin (Invitrogen)-coated chamber slides and induced to differentiate in Megacell Dulbecco's modified eagle's medium containing 2% fetal bovine serum. Cells were fixed with 4% paraformaldehyde at 7 days after the commencement of differentiation. Immunostaining with antibodies against myosin (MF20, DSHB, 1:100), Pax7, and dystrophin (Fisher Scientific, RB9024P1, 1:200) was performed as described above. Images were acquired using Metamorph software (Molecular Device, Sunnyvale, CA) using a Leica microscope (Leica Microsystems, Milton Keynes, UK).
In vivo transplantation and analysis
Intramuscular transplantation of hCD133 + cells. Four-to eight-week-old Rag2-/γ chain-/C5-mice [43] [44] [45] were used as recipients in this study. Hind legs were irradiated with 18Gy 3 days before cell transplantation. 20, 46 On the day of transplantation, TA muscles were cryodamaged with three freeze-thaw cycles using a cryoprobe prechilled in liquid nitrogen.
14 5 × 10 5 hCD133 + cells/5 µl culture medium were injected into each TA with a Hamilton syringe.
For analyzing donor cell survival, their contribution to regenerated muscle fibers and satellite cells, three groups of recipient mice (both TA muscles of each mouse) were transplanted with CD133 + cells at mpd 7.15-8.29 maintained in three different proliferation media: medium 1 (n = 8), medium 2 (n = 6), and medium 3 (n = 6). Muscles were removed for analysis 1 month after grafting.
For comparison of the in vivo muscle regenerative potential of cells at different mpds, CD133 + cells at mpd 7.15-8.29 (early passage cells) or mpd 18.19 (late passage cells) were transplanted to recipient mice as described above. Injected muscles were analyzed at 1 month (n = 6 for early passage cells and n = 5 for late passage cells) and 3 months (n = 4 for early passage cells and n = 5 for late passage cells) after transplantation.
For the functional satellite cell assay, CD133 + cells at mpd 7.15-8.29 were transplanted into irradiated and cryodamaged TA muscles of a group of seven mice as described above. Eight weeks (n = 3) and 14 weeks (n = 4) after transplantation, the right TA of the recipient mice was injected with 10 µl of 10 µg/µl notexin, a myotoxin that destroys muscle fibers but spares other resident muscle cells, including satellite cells, to induce a secondary injury to the grafted, regenerated muscle. 2 The contralateral, grafted muscle was not injected with notexin (control). The mice were analyzed 1 week after notexin treatment and analyzed as described below.
Analysis of muscle sections. Grafted TA muscles were dissected and frozen in isopentane chilled in liquid nitrogen. Eight micrometers transverse cryosections were taken throughout the muscle and stained with antibodies to human spectrin (Vector labs, VP-S283, 1:100, Peterborough, UK), human lamin A/C (Vector labs, VP-L550, 1:100), pan-laminin (Sigma, L9393, 1:1000), Pax7, MyoD, human neonatal myosin (Vector labs, VP-M666, 1:100) followed by corresponding secondary antibodies (Alexa 488-conjugated goat antimouse IgG1, Alexa 594-conjugated goat antimouse IgG2b, Alexa 647, or 594 conjugated goat antirabbit IgG (H+L), etc., Invitrogen). Images were captured with MetaMorph software using a Leica microscope. Four-colour images were acquired using a Zeiss LSM 710 confocal microscope (Carl Zeiss, Cambridge, UK). The number of human lamin A/C + nuclei, human spectrin + fibers, human spectrin + fibers containing human lamin A/C + nuclei (as a confirmation that the spectrin + fibers were of donor origin) were counted in representative transverse sections using MetaMorph software to quantify the number of donor cells and their contribution to muscle regeneration. The data were analyzed by one-way analysis of variance or Mann-Whitney test using graphpad prism5 software (GraphPad Software, La Jolla, CA). In the reinjury experiment, the number of small fibers that were strongly-expressing human neonatal myosin (newly regenerated muscle fibers) was counted and normalized to the number of human spectrin + fibers in the same section as a proportion of total fibers of human origin, and the ratio in the right TA (experimental) muscle and the left TA (control) muscle of each mouse was compared and analysed using paired t-test.
Ethics. Tissue sampling was approved by the NHS national Research Ethics Service, Hammersmith, and Queen Charlotte's and Chelsea Research Ethics Committee. Setting up of a rare diseases biological samples bank (biobank) for research to facilitate pharmacological, gene, and cell therapy trials in neuromuscular disorders REC reference number: 06/Q0406/33, in compliance with national guidelines regarding the use of biopsy tissue for research. All patients or their legal guardians gave written informed consent. Figure S1 . Morphology of cultured hCD133 + cells maintained in medium 1 (a), medium 2 (b) and medium 3 (c). Figure S2 . Characterization of bulk cultured hCD133 + cells by immunostaining of various lineage markers (all in green). Figure S3 . Characterization of cultured hCD133 + cells by FACS analysis.
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